More recently, 2 studies demonstrated that a genetic defect of CYP2C19 led to an approximately 2 times higher risk of subsequent cardiovascular events, including nonfatal myocardial infarction and stroke.[26,27] Our study also demonstrated that T variations at the C34T and G52T sites of P2RY12 were associated with a 2.7 and 5.6 times greater risk for CVD events after PCI, respectively. This evidence concerns the gene CYP2C19 and stroke disorder.